Thursday, 22nd October Australian and New Zealand Obesity Society Annual Scientific Conference 2026

Participate in a health check by ESSA Accredited Exercise Physiologists (AEPs) and see how you compare to the 'average Australian'. Find the Exercise & Sports Science Australia (ESSA) team to get data driven insights about your muscle and joint health. Learn how AEPs support those living with overweight and obesity to maintain muscle and bone health while using or not using GLP-1 like medications.

• Talk title to come - Kate McBride
• Does the uptake of GLP-1 RA medications like Ozempic and Mounjaro risk nutrition support being considered ‘low- value’ healthcare? - Clare Collins
• Targeting Class B1 GPCRs for Metabolic Diseases - Denise Wootten

• Healthy food policy for people and the planet - Simone Pettigrew

• Efficacy and safety of survodutide for the treatment of obesity in adults without diabetes: primary results from the SYNCHRONIZE®-1 phase 3 trial - Elif Ekinci
• Semaglutide Reduces Body Weight Regardless of Menopause Status: STEP and OASIS 4 Post Hoc Analysis - Sarah Glastras
• Early Responders to Semaglutide 7.2 mg: A Post Hoc Analysis of the STEP UP Trial in Adults with Obesity - Tomasz Block
• Safety, tolerability, pharmacokinetics and pharmacodynamics of eloralintide and tirzepatide co-administered as once-weekly subcutaneous injections - Samantha Hocking
• Cardiometabolic parameters by the degree of maintenance of weight reduction in tirzepatide-treated adults with obesity: post hoc study of SURMOUNT MAINTAIN Trial - Adam Nelson
• Menopausal Stage and Weight Outcomes with Orforglipron vs Placebo: Post-Hoc Subgroup Analysis from ATTAIN-1 and ATTAIN-2 - Paige Lanyon-Roberts

• Child and maternal predictors of cardiovascular profiles among children from two cohorts: findings from The Barwon Infant Study and the European Youth Heart Study - Saeed Ghobadi
• The acceptability and implementation of screening children and adolescents for type 2 diabetes: the perspectives of health professionals - Jessica Hardt
• Change in 24-hour movement behaviours in children aged 4-16 after participation in a multicomponent, community-based, family focused Healthy Lifestyle Program pilot in Perth, Western Australia  - Katie M Iwanowski
• Change in diet quality, food group and nutrient intakes of children aged 4-16 after participation in a multicomponent, community-based, family focused healthy lifestyle program pilot in Perth, Western Australia - Katie M Iwanowski
• Adiposity and lean mass interactions in relation to diabetes: BMI–DXA concordance and body composition phenotypes in U.S. adults - Tadesse Asmamaw Dejenie
• Physical activity and life expectancy in Queensland Australia - a lifetable analysis - Lennert Veerman

• OPTIMAP one year on: outcomes and system impact of a digitally enabled obesity care model in south australia - Katie Belobrajdic
• Homeostatic feeding and reward: investigating the role of a neuronal antenna in obesity - Adélaïde Bernard
• Digital Marketing Techniques and Food Choice Drivers: Real-time insights into young people’s online food delivery service use in Australia. - Adyya Dr Gupta
• Co-design and Implementation of a Regional Adult Obesity Model of Care in Queensland: Improving Access, Quality and Sustainability in Public Health Services - Carrie-Anne Lewis
• Real-world effectiveness of hospital-funded incretin-based pharmacotherapy for the management of severe obesity in public multidisciplinary weight management programs - Sarah Hirst
• Tirzepatide attenuates renal injury in a mouse model of insulin-deficient diabetes with obesity - Amanda R Purcell

Obesity management is entering a new era. Join for an engaging exploration of current and emerging evidence for semaglutide in obesity care.

This session will review outcomes from the clinical development programme, including weight management, cardiometabolic health and long-term disease risk, alongside clinical experience and recent advances in treatment. The discussion will also examine newer data on alternative formulations and evolving treatment approaches, before looking ahead to the next generation of obesity therapies.

Drawing on perspectives from both specialist and primary care settings, A/Prof Nelson and Dr South will share practical insights on translating evidence into practice. As the therapeutic landscape expands beyond a one-size-fits-all approach, learn how personalised treatment selection, sequencing, patient engagement and long-term management can help optimise outcomes for people living with obesity.

• Too Deadly for Diabetes: A Community-Led Model for Better Chronic Disease Outcomes - Ray Kelly
• I've tried yarning, what next? Extending practice through Indigenous Methodology. - Kai Wheeler
• Seeing people beyond nutrition: Insights for whānau-centred dietetic care in Aotearoa New Zealand - Nikki Renall

• First, Do No Harm: Rethinking Nutrition Messaging in Schools to Support Both Physical and Mental Health - Gabriella Heruc
• Promoting Physical Activity in Organised Settings: Navigating Complexity and Context - Michalis Stylianou
• Obesity prevention is no longer needed in schools - a case study from the Systems Thinking with Active Implementation Research (STAIR) project - Colin Bell
• On-site breakfast provision quality in early childhood education and care services: a cross-sectional survey of Victorian centres - Seon Park

• Protein kinase C epsilon in the modulation of insulin-dependent and -independent glucose homeostasis - Carsten Schmitz-Peiffer
• Talk title to come - Scott Summers
• Diet- and metabolic state-dependent remodelling of the mouse brain lipidome - Yi Wang

• Exercise and Musculoskeletal Health in the GLP-1RA Era: Clinical Implications, Challenges, and Opportunities - Robin Daly
• Bringing a precision medicine lens to prevent the intergenerational transmission of obesity - Leanne Venable
• Exploring the metabolic switching theory of intermittent fasting in humans with obesity - Kai Liu
• More Than Weight Loss: Clinically Meaningful Functional Improvements During GLP-1 Therapy  - William Beningfield

Panel discussion to follow speaker presentations

• Prevention 2.0 - Robyn Littlewood
• Talk title to come - Caroline Miller

• Macrophage Colony Stimulating Factor (CSF1) promotes resolution of fibrosis and steatosis in preclinical models of metabolic dysfunction-associated steatotic liver disease. - Sahar Keshvari
• How do adipose eosinophils become distinct from blood eosinophils and how can we exploit these differences to identify new obesity therapeutic targets? - Kate Quinlan
• Dietary saturated fatty acids impair immune response to Influenza A infection in people living with obesity, increasing interleukin-1β and reducing interferon-⍺. - Blair J Westbury

Ticket Event. Pre-registration required